Drugs designed to remove worn-out, aging cells may help old skin recover faster from damage, according to a study published in . Aging (Aging-United States). The study, titled “Topical ABT-263 treatment reduces aging in aging skin and improves subsequent wound healing,” suggests that targeting “zombie cells” in the skin may one day improve healing after surgery, injury, or chronic wounds in older adults.
The research team included Maria Shvedova, Rex Jeya Rajkumar Samdavid Thanapore, Joy Ha, Jannat Dhillon, Grace H. Singh, Jack Crouch, Adam C. Gower, Sami Glitori, and Daniel S. Roe of Boston University’s Aram V. Chobanian School of Medicine and Edward Avedisyan School of Medicine.
remove aged cells
As the skin ages, damaged cells may accumulate instead of dying. These cells, known as senescent cells, no longer function normally but remain active enough to interfere with nearby tissues. Over time, inflammatory signals and other molecules can be released that weaken the skin’s ability to repair itself.
Researchers tested whether ABT-263, a senolytic treatment, could alleviate this burden when applied directly to aging skin. Senolytic drugs are designed to selectively eliminate senescent cells, which are associated with aging, inflammation, and delayed tissue repair.
In the study, ABT-263 was administered to the skin of elderly mice for five days. After treatment, signs of cellular aging in the skin decreased. Then, when the researchers made small wounds, the treated mice healed faster than untreated mice.
By day 24, 80% of mice treated with ABT-263 had completely healed their wounds, compared with 56% of untreated mice.
Astonishing improvement in healing power
One of the more unexpected findings was that ABT-263 temporarily increased skin inflammation. Inflammation is often considered harmful, especially when it becomes chronic. But in this case, short bursts seemed to help prepare the skin for repair.
The treatment appears to have awakened healing pathways that are normally dulled in older tissues. Gene activity was increased in areas associated with wound repair, including collagen production, blood vessel growth, tissue remodeling, and other processes needed to close and strengthen injured skin.
This is important because skin aging is not just about wrinkles and thinning of the skin. Also, your reactions slow down after an injury. A slow response can increase the risk of prolonged post-surgical recovery, delayed wound closure, and complications in people with chronic skin injuries.
Why topical treatment is important
ABT-263 has attracted interest because it can target senescent cells, but oral senolytics circulate throughout the body and can cause side effects. Applying the drug directly to the skin may allow for a more intensive approach.
In this study, topical administration of ABT-263 reduced signs of aging in old mice, but a similar effect was not seen in young mice. This suggests that the treatment may be most effective in older tissues where senescent cells have accumulated.
Researchers believe this targeted approach may be particularly useful before surgery and in people at risk of poor wound healing. Rather than waiting for scars to heal, treatments may one day be able to prepare aging skin in advance.
“Our study highlights the potential of topical senolytic treatments to promote wound healing in aging skin and represents a potentially promising strategy for preoperative care.”
Points of new research in the same direction
Since this 2024 study, the broader field has continued to move toward localized senolytic strategies for skin repair. 2025 review Review of aging research described cellular senescence as the main cause of skin aging and skin diseases, while pointing out that senolytic and related treatments could be useful tools to target harmful senescent cells in the skin.
A 2026 study took this idea further in diabetic wound healing, a major medical challenge characterized by chronic inflammation, poor blood vessel growth, and cellular senescence. Researchers developed a topical wound dressing containing ABT-263 and reported that it reduced the burden of senescent cells and improved healing in diabetic mice, with no detectable systemic toxicity in that model.
At the same time, scientists are careful not to portray senescent cells as purely bad. 2024 Frontiers of immunology This study highlighted that although senescence may play a useful role during normal wound repair, persistent senescent cells can contribute to chronic wounds, fibrosis, and abnormal healing. The challenge is timing and precision. This means removing harmful residual cells without interfering with helpful early repair signals.
Promise with important attention
This discovery is interesting, but still in its early stages. Skin studies of ABT-263 were conducted in mice, but more research is needed before scientists can know whether the treatment is safe or effective in humans.
Researchers also need to answer important questions about dosage, timing, long-term safety, and whether the benefits apply to human skin, surgical recovery, diabetic wounds, or other slow-healing conditions.
Still, the idea is powerful. By removing cells that block skin aging, topical senolytic treatments may one day allow the body to repair itself more quickly and effectively. For older adults facing surgery or chronic wounds, this could make healing less difficult, less risky, and much faster.
